| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC2103 |
| Trial ID | NCT03938987 |
| Disease | Acute Monocytic Leukemia | Non-Hodgkin's Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19 CAR-T cells |
| Generation | 2nd |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) |
| Year | 2020 |
| Country | Canada |
| Company sponsor | University of Alberta |
| Other ID(s) | ACIT001/EXC002 |
| Vector information | |||||
|
|||||
| Cohort 1 | |||||||||||||
|
|||||||||||||